Van Cutsem E, Peeters M
Département de médecine interne, hôpital universitaire Gasthuisberg, Louvain, Belgique.
Bull Cancer. 1998 Dec;Spec No:33-7.
Irinotecan or CPT11 is a topoisomerase 1 inhibitor. The European and American regimens of irinotecan in monotherapy are different: respectively 350 mg/m2 i.v. every 3 weeks and 125 mg/m2 i.v. weekly (4 weeks out of 6). In a large phase 2 programme an important activity has been shown in metastatic colorectal cancer. In 5FU resistant colorectal cancer an objective response rate of 13% has been shown. This was associated with a long median time of response, a long median time to progression and a long median survival. More than 40% of patients had also a stabilisation in second line treatment. This interesting activity was the basis for the phase 3 studies that have positioned irinotecan as the standard treatment in 5FU resistant colorectal cancer. The response rate in first line treatment of colorectal cancer varies between 18% and 32%. The main side effects are neutropenia and delayed diarrhea.
伊立替康（CPT11）是一种拓扑异构酶1抑制剂。伊立替康在欧美的单药治疗方案有所不同：分别为每3周静脉注射350mg/m²和每周静脉注射125mg/m²（6周内4周用药）。在一项大型2期研究中，已显示出其在转移性结直肠癌中有显著活性。在对5-氟尿嘧啶（5FU）耐药的结直肠癌中，客观缓解率为13%。这与较长的中位缓解时间、较长的疾病进展时间和较长的中位生存期相关。超过40%的患者在二线治疗中病情也得到稳定。这种显著活性是开展3期研究的基础，这些研究已将伊立替康定位为5FU耐药结直肠癌的标准治疗方法。结直肠癌一线治疗的缓解率在18%至32%之间。主要副作用是中性粒细胞减少和迟发性腹泻。
